Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers in gynecologic malignancies.

J P Dutcher1, S Wadler, P H Wiernik

  • 1Department of Oncology, Montefiore Medical Center, Bronx, NY 10467.

The Yale Journal of Biology and Medicine
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019
Same author

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Characterization of bone metastases in patients with renal cell cancer.

BJU international·2004
Same author

Accelerated and blastic phase of chronic myeloid leukemia.

Current treatment options in oncology·2002
Same author

Phase I study of recombinant human CD40 ligand in cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Angiogenesis and melanoma.

Current oncology reports·2001
Same journal

Chrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery.

The Yale journal of biology and medicine·2026
Same journal

Musicality is Preserved in Neurodegeneration.

The Yale journal of biology and medicine·2026
Same journal

Burden of Neurological Disorders in Resource-Limited Settings: Lessons from Pakistan for Global Neurology.

The Yale journal of biology and medicine·2026
Same journal

Comparative Analysis of Prenatal Stress Models: Placental and Neurodevelopmental Outcomes in Mice.

The Yale journal of biology and medicine·2026
Same journal

Computational Investigation of Flavonoid-Associated Molecular Pathways in Astrogliosis Modulation.

The Yale journal of biology and medicine·2026
Same journal

Regulation and Interaction Among SOCS1 and SOCS3 by MicroRNAs in Multiple Sclerosis: A Review and <i>In Silico</i> Analysis.

The Yale journal of biology and medicine·2026
See all related articles

Biological therapy, including immunotherapy and interferon, shows promise for treating ovarian and cervical cancers by stimulating immune responses or targeting viral infections. Pre-clinical and clinical data support its potential, especially for chemotherapy-resistant or virally-induced tumors.

Area of Science:

  • Oncology
  • Immunology
  • Biotherapy

Background:

  • Biological therapy is being explored for various cancers.
  • It aims to enhance the immune system's response to malignant cells.
  • This approach may be effective against small-volume or chemotherapy-resistant tumors.

Purpose of the Study:

  • To review pre-clinical and clinical data on biological therapy for malignancies.
  • To evaluate immunotherapy for advanced ovarian cancer.
  • To investigate interferon's role in cervical cancer due to its antiviral properties.

Main Methods:

  • Review of pre-clinical studies.
  • Analysis of clinical trial data.
  • Examination of biological therapy mechanisms in cancer treatment.

Related Experiment Videos

Main Results:

  • Immunotherapy may be effective in advanced ovarian cancer post-cytoreduction.
  • Biological therapy offers potential for localized, chemotherapy-resistant ovarian cancer.
  • Interferon is being studied for cervical cancer's viral origins.

Conclusions:

  • Biological therapy presents a viable option for specific cancer types.
  • Further research is warranted based on existing pre-clinical and clinical evidence.
  • This modality holds promise for challenging malignancies like ovarian and cervical cancers.